Frequently I have complained that the terms "typical and atypical" or "first generation and second generation" antipsychotics were not very helpful. When I give chalk talks to junior residents and interns about antipsychotics, this is one of the first things that I note. It is the medicines relative affinities for different receptors that appear to make the difference, not whether they were discovered prior to 1980 or not. A few weeks ago, I was lucky enough to encounter a paper that was published in April of 2023 by McCutcheon et al in Biological Psychiatry titled "Data-Driven Taxonomy for Antipsychotic Medication: A New Classification System." In this episode, I use their results to guide a discussion of variability in target effects and side effects of different groups of antipsychotics.Please leave feedback at https://www.psydactic.com or send any comments to feedback@psydactic.com.References and readings (when available) are posted at the end of each episode transcript, located at psydactic.buzzsprout.com. All opinions expressed in this podcast are exclusively those of the person speaking and should not be confused with the opinions of anyone else. We reserve the right to be wrong. Nothing in this podcast should be treated as individual medical advice.
Top comments
A resource for psychiatrists and other medical or behavioral health professionals interested in exploring the neuroscientific basis of psychiatric disorders, psychopharmacology, neuromodulation, and other psychiatric interventions, as well as discussions of pseudoscience, Bayesian reasoning, ethics, the history of psychiatry, and human psychology in general.This podcast is not medical advice. It strives to be science communication. Dr. O'Leary is a skeptical thinker who often questions what we think we know. He hopes to open more conversations about what we don't know we don't know.Find transcripts with show-notes and references on each episodes dedicated page at psydactic.buzzsprout.com.You can...